A prospective study to evaluate the effect of allopurinol on muscle energetics in primary sarcopenia

niversity of Dundee (UK)0 个研究点目标入组 124 人开始时间: 2012年4月17日最近更新: 2020年6月8日

试验速览

暂无简介。

•Current inclusion criteria as of 11/11/2014:
•1. Age 65 years and over
•2. 6-Minute Walk Distance <400 m
•Previous inclusion criteria:
•1. Age 65 and over
•2. Muscle strength (grip strength <20kg women;<30kg men) AND physical performance (Short Physical Performance Battery test score less than or equal to 8/12). This will ensure both that the study population have sarcopenia according to European consensus guidelines
•3. Gait speed less than 0.8m/s

•Current exclusion criteria as of 11/11/2014:
•1. Documented history of peripheral arterial disease
•2. Pre-existing diagnosis of severe heart failure (LVEF <35%)
•3. Malignancy under active treatment (excluding basal cell carcinoma)
•4. Severe COPD (physician diagnosis)
•5. Intolerance to allopurinol
•6. Individuals with Active Acute Gout currently taking allopurinol; or those who have stopped taking allopurinol =1 month previously for this condition.
•7. On long-term high-dose steroids (eq. Prednisolone >10 mg/day due to risk of steroid-induced myopathy and osteoporosis)
•8. Immobility that would render the patient incapable of doing the Short Physical Performance Battery Test (SPPB) or 6MWT
•9. Patients who have participated in any other clinical drug trial within the previous 30 days will be excluded
•10. Cognitive impairment precluding informed consent
•11. Any other considered by a study physician to be inappropriate for inclusion
•Previous exclusion criteria:
•1. Previously enrolled into the study
•2. Pre-existing diagnosis of heart failure or any malignancy (excluding basal cell carcinoma)
•3. Documented intolerance to allopurinol
•4. Immobility that would render the patient incapable of doing the Short performance Battery Test (SPBT)

发起方

niversity of Dundee (UK)